{
    "clinical_study": {
        "@rank": "148083", 
        "acronym": "HCF-CMP-CHF", 
        "arm_group": {
            "arm_group_label": "Subjects with CHF follow-up", 
            "description": "Subjects with Hospital-Community-Family-Care Management Platform online and those with the clinic follow up."
        }, 
        "brief_summary": {
            "textblock": "The purpose of this study is to determine whether the Hospital-Community-Family-Care\n      Management Platform for Chronic Heart Failure reduces the mortality, readmission rates and\n      costs of the subjects with CHF."
        }, 
        "brief_title": "Hospital-Community-Family-Care Management Platform for Chronic Heart Failure", 
        "completion_date": {
            "#text": "September 2016", 
            "@type": "Anticipated"
        }, 
        "condition": "Chronic Heart Failure", 
        "condition_browse": {
            "mesh_term": "Heart Failure"
        }, 
        "detailed_description": {
            "textblock": "(1)Indication:Chronic Heart Failure.(2) Objectives: Primary objective is to evaluate the\n      efficacy of the Hospital-Community-Family-Care Management Platform online compared with the\n      regular clinic follow up in subjects with CHF (II-III class by NYHA).Secondary objectives is\n      to assess the safety of the Management Platform online in subjects with CHF.(3) Study\n      design: Prospective, randomized,controlled study with two follow up management groups: 1)\n      the Hospital-Community-Family-Care Management Follow up Online;2) the regular monthly clinic\n      follow up.Study population:Totally 1000 male and female subjects with CHF (II-III functional\n      classes according to NYHA classification).(4) Quality assurance plan that addresses data\n      validation and registry procedures, including any plans for site monitoring and auditing.(5)\n      Data checks to compare data entered into the registry against predefined rules for range or\n      consistency with other data fields in the registry.(6) Source data verification to assess\n      the accuracy, completeness, or representativeness of registry data by comparing the data to\n      external data sources.(7)Standard Operating Procedures to address registry operations and\n      analysis activities, such as patient recruitment, data collection, data management, data\n      analysis, reporting for adverse events, and change management.(8)Duration of follow up: The\n      total follow-up time shall be 12 months.(9)Safety Assessment:Safety of the study will be\n      evaluated by the following assessments: 1)Subject examinations (during the follow up period\n      and extending up to 2 week after the end of the study) consisting of a subject interview\n      (including direct questioning about adverse events), physical examination, assessment of\n      body weight, Electrocardiogram (ECG) and echocardiogram (UCG), Left ventricular ejection\n      fraction, assessed by echocardiography, The N-terminal prohormone of brain natriuretic\n      peptide (NT-proBNP), a peptide hormone whose plasma concentration is inversely related to\n      the severity of HF, NYHA functional status, assessed by subject interview, Quality of life\n      (QoL), assessed by the Minnesota Living with Heart Failure questionnaire (MLHFQ), a\n      validated questionnaire assessing QoL in subjects with heart failure. 2)Evaluation of\n      clinically relevant safety laboratory parameters, such as complete blood count, serum\n      creatinine, electrolytes, and liver enzymes.Any Adverse Events (AE) or Serious Adverse\n      Events (SAE) and its potential causal relationship with the study will be recorded and\n      evaluated.(10)"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:Inclusion Criteria:to be considered eligible to participate in this\n        study, a subject must meet the inclusion criteria listed below at the time of screening\n        and randomization:\n\n          1. Male and female subject\u226518 years of age.\n\n          2. History of CHF for \u22653 months with NYHA functional class II-III.\n\n          3. Left ventricular ejection fraction \u226445% as assessed by echocardiogram.\n\n          4. Treatment of CHF with stable and optimal pharmacological therapy according to Chinese\n             guidelines for treatment of CHF. In general, optimal treatment will include a\n             beta-blocker and an ACE inhibitor and/or an angiotensin receptor blocker, unless not\n             tolerated. Medical therapy is defined as stable, if the subject has not started a new\n             CHF drug class and the dose of drugs taken have not been changed during the 3 months\n             prior to screening and randomization.\n\n          5. Ability to understand the requirements of the study and willingness to provide\n             written informed consent (IC), and agreement to abide by the study restrictions and\n             return for the required assessments.\n\n          6. Subjects are located in our coverage of the remote monitoring system.\n\n        Exclusion Criteria:To be eligible for entry into the study, the subject must not meet any\n        of the exclusion criteria listed below at screening and randomization:\n\n          1. Abnormal renal or hepatic function, defined as ALT\u2265100 u/L, serum creatinine\n             >3.0mg/dL, serum albumin \uff1c2.5g/L.\n\n          2. Hemoglobin concentration\u22648.0g/dL.\n\n          3. Obesity (body mass index >35kg/m2).\n\n          4. Heart failure primarily due to valvular heart disease, or clinically significant\n             valvular heart disease that is expected to require surgical correction within 12\n             months after randomization.\n\n          5. Implantable cardiac defibrillator (ICD) within 30 days prior to randomization, or\n             initiation of cardiac resynchronization therapy (CRT with/without ICD) within 30 days\n             prior to randomization.\n\n          6. Routinely scheduled IV infusions for HF (e.g., inotropes, vasodilators, diuretics).\n\n          7. Acute myocardial infarction or cerebrovascular accident within 6 months prior to\n             randomization.\n\n          8. Percutaneous intervention (coronary, cerebrovascular, aortic) within 6 months prior\n             to randomization.\n\n          9. Major surgery, including thoracic or cardiac surgery, within 3 months prior to\n             randomization.\n\n         10. Symptomatic tachyarrhythmia with an uncontrolled ventricular response (>100 bpm at\n             rest) or an untreated symptomatic bradyarrhythmia within 1 month prior to\n             randomization.\n\n         11. Hypertrophic obstructive cardiomyopathy, active myocarditis, constrictive\n             pericarditis.\n\n         12. Likelihood of cardiac transplantation within 12 months after randomization.\n\n         13. Peripheral artery disease, which interferes with 6 minutes walking test.\n\n         14. Chronic obstructive pulmonary disease, which interferes with 6 minutes walking test.\n\n         15. History of major organ transplant (e.g., lung, liver, heart, bone marrow) or renal\n             replacement therapy.\n\n         16. Serious anaemia secondary to acute or chronic bleeding.\n\n         17. Whole blood or red blood cell (RBC) transfusion within 8 weeks prior to\n             randomization.\n\n         18. Severe concomitant non-cardiovascular disease that is expected to reduces life\n             expectancy to less than 3 years.\n\n         19. History of any neoplastic disease.\n\n         20. Known active systemic hematologic disease (e.g., sickle cell anemia, myelodysplastic\n             syndromes, hematologic malignancy, myeloma, hemolytic anemia), hemolysis due to any\n             cause, thalassemia.\n\n         21. Untreated hypo- or hyperthyroidism, adrenal insufficiency, active vasculitis due to\n             collagen vascular disease.\n\n         22. Use of any erythropoietic protein (eg, rHuEPO) within 12 weeks prior to\n             randomization.\n\n         23. Pregnancy (e.g. positive human chorionic gonadotropin [HCG] test) or active\n             lactation.\n\n         24. Currently or recently (<30 days) enrolled in clinical trials or other investigational\n             devices, or currently receiving other investigational agent(s) or procedure(s).\n\n         25. Disorder that compromises the ability of the subject to give written informed consent\n             or to comply with study procedures."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "80 Years", 
            "minimum_age": "18 Years", 
            "sampling_method": "Non-Probability Sample", 
            "study_pop": {
                "textblock": "1000 subjects with chronic, moderate heart failure (NYHA functional class II-III) with\n        reduced ejection fraction (\u226445%) will be enrolled (500 randomly allocated to receive and\n        500 to receive placebo in addition to standard therapy). Determination of study\n        eligibility will be established by the Investigator on the basis of the inclusion and\n        exclusion criteria."
            }
        }, 
        "enrollment": {
            "#text": "1000", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "December 21, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02029287", 
            "org_study_id": "BL2013022"
        }, 
        "intervention": {
            "arm_group_label": "Subjects with CHF follow-up", 
            "description": "Hospital-Community-Family-Care Management Platform Online: the remote  monitoring service platform on line based on community and family for subjects with CHF under the guidance of the regional central hospital", 
            "intervention_name": "Hospital-Community-Family-Care Management Platform Online", 
            "intervention_type": "Other"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": [
            "Chronic heart failure", 
            "telemedicine", 
            "health service platform"
        ], 
        "lastchanged_date": "January 5, 2014", 
        "location": {
            "contact": {
                "last_name": "Jianhua Shen, Doctor", 
                "phone": "+86 0514 87373367"
            }, 
            "facility": {
                "address": {
                    "city": "Yangzhou", 
                    "country": "China", 
                    "state": "Jiangsu", 
                    "zip": "225001"
                }, 
                "name": "Department of cardiovascular medicine,Northern Jiangsu Hospital"
            }, 
            "investigator": [
                {
                    "last_name": "Lei Sun, Master", 
                    "role": "Sub-Investigator"
                }, 
                {
                    "last_name": "Ye Zhu, Master", 
                    "role": "Sub-Investigator"
                }, 
                {
                    "last_name": "Shuhang Miao, Bachelor", 
                    "role": "Sub-Investigator"
                }, 
                {
                    "last_name": "Yi Zhang, Master", 
                    "role": "Sub-Investigator"
                }, 
                {
                    "last_name": "Zhengyu Bao, Doctor", 
                    "role": "Sub-Investigator"
                }, 
                {
                    "last_name": "Ming Gu, Master", 
                    "role": "Sub-Investigator"
                }, 
                {
                    "last_name": "Hui Li, Bachler", 
                    "role": "Sub-Investigator"
                }, 
                {
                    "last_name": "Fei Hang, Master", 
                    "role": "Sub-Investigator"
                }
            ], 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "China"
        }, 
        "number_of_groups": "1", 
        "official_title": "Remote Prevention and Treatment Based on Community Under the Guidance of Regional Central Hospital for Patients With Chronic Heart Failure", 
        "other_outcome": [
            {
                "description": "Number of subjects requiring drug or dose changes to intensify concomitant therapy due to worsening of heart failure (HF).", 
                "measure": "heart failure worsening", 
                "safety_issue": "Yes", 
                "time_frame": "one year"
            }, 
            {
                "description": "Hospitalization rate associated with heart failure", 
                "measure": "Hospitalization rate", 
                "safety_issue": "Yes", 
                "time_frame": "one year"
            }, 
            {
                "description": "Costs of medications associated with heart failure", 
                "measure": "Costs of medications", 
                "safety_issue": "Yes", 
                "time_frame": "one year"
            }
        ], 
        "overall_contact": {
            "email": "sbyygx189@gmail.com", 
            "last_name": "Xiang Gu, Doctor", 
            "phone": "+86 0514 87373366"
        }, 
        "overall_official": [
            {
                "affiliation": "Department of cardiovascular medicine", 
                "last_name": "Xiang Gu, Docter", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "Department of cardiovascular medicine", 
                "last_name": "Jianhua Shen, Docter", 
                "role": "Principal Investigator"
            }
        ], 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Institutional Review Board", 
            "has_dmc": "Yes"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "June 2016", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Number of subjects with all cause death", 
            "measure": "all cause mortality", 
            "safety_issue": "Yes", 
            "time_frame": "one year"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02029287"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Northern Jiangsu Province People's Hospital", 
            "investigator_full_name": "Xiang Gu", 
            "investigator_title": "Professor of Cardiology, Director of Cardiovascular Medicine", 
            "responsible_party_type": "Sponsor-Investigator"
        }, 
        "secondary_outcome": {
            "description": "number of subjects with heart failure - related visits", 
            "measure": "Heart failure morbidity", 
            "safety_issue": "Yes", 
            "time_frame": "one year"
        }, 
        "source": "Northern Jiangsu Province People's Hospital", 
        "sponsors": {
            "collaborator": [
                {
                    "agency": "Science and Technology Department of Jiangsu Province", 
                    "agency_class": "Other"
                }, 
                {
                    "agency": "Yangzhou Municipal Health Bureau", 
                    "agency_class": "Other"
                }
            ], 
            "lead_sponsor": {
                "agency": "Xiang Gu", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "December 2013", 
        "study_design": "Observational Model: Ecologic or Community, Time Perspective: Prospective", 
        "study_type": "Observational [Patient Registry]", 
        "target_duration": "12 Months", 
        "verification_date": "January 2014"
    }
}